Clinical Trial Update: Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus [Phase 3]

View source ↗

Summary

Phase 3 trial update for epithelium-on corneal cross-linking in subjects aged 8 to 45 with keratoconus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Keratoconus

Drugs mentioned

• Epion Therapeutics (epithelium-on corneal cross-linking)

Snippet

Sponsor: Epion Therapeutics | Conditions: Keratoconus | Phase 3 | Status: COMPLETED